News

China's 2026 supply chain rules mean routine US trade compliance can now trigger Chinese export restrictions.

Cate Lockhart shares how manufacturers should communicate across mixed RWE data sources and what guardrails AI needs before payers can trust it.

In this week's Pharma Pulse, UPS commits $48 million to cold chain infrastructure, AbbVie moves to acquire Apogee Therapeutics in a $10.9 billion deal, and more.

In this special episode of Pharma Pulse, Rohit Tripathi breaks down how companies should be scenario planning ahead of the first USMCA joint review which begins on July 1.

As hub transitions accelerate and digital tools reshape how support is delivered, four patient services experts weigh in on what's driving change in 2026, and what manufacturers need to get right to keep patients on therapy.

Cate Lockhart explains why pharma-generated RWE quality isn't the issue, and how AMCP Standards are closing the communication gap with payers.

As PBM pressure mounts and formulary bidding wars squeeze manufacturers, a direct access marketplace model offers drug makers a path to compete on efficacy, price and real-world outcomes.

The investment adds 27 temperature-controlled freight facilities across the Americas, Europe, and Asia as demand for biologics distribution infrastructure continues to climb.

AMCP's Cate Lockhart on why only 18% of payers regularly use real-world evidence, and what the new AMCP RWE Standards are doing to change that.

PwC's Philip Sclafani discusses oral GLP-1 cost exposure, oncology drug spend under the medical benefit, and his outlook on PBM reform.

PwC’s Philip Sclafani discusses rising payer cost exposure, GLP-1 growth, and why pharmacy spending is outpacing medical cost trend heading into 2027.

PwC projects drug spending will outpace medical trends in 2027, driven by GLP-1s and oncology. Here's what it means for market access.

In this week's Pharma Pulse, Europe’s drug pricing standoff intensifies, CMS moves to formalize Medicare negotiation rules, FDA expands OTC naloxone, and DSV launches a new pharma air route.

Cold chain packaging was built for a stable world. As disruption becomes the norm, pharma logistics teams are rethinking what control actually means, and when it has to happen.

CMS' proposed framework for 2029 and beyond closes a potential formulation loophole and raises the stakes for launch planning.

Behavioral and engagement insights are helping biopharma companies design more personalized patient support programs that improve persistence and long-term outcomes.

As the US and Iran reach a framework agreement to reopen the Strait of Hormuz, Pharmaceutical Commerce breaks down what the deal means for pharmaceutical supply chains.

Will Shrank, MD, breaks down why payers, providers, and manufacturers are all struggling to keep pace with a rapidly expanding cell and gene therapy pipeline — and what it will take to fix it.

A new BGH survey shows some large employers are pulling back on GLP-1 weight-loss coverage in 2027 as rising costs and utilization outpace anticipated savings.

AI-powered automation is transforming pharmacovigilance, cutting AE case intake time amid record FAERS volumes and new FDA/EMA regulatory guidance.

In this week's Pharma Pulse, USP's annual shortages report reveals a sharp rise in drug discontinuations, J&J and Roche commit billions to protein degrader platforms, and more.

X-Therma's end-to-end biopreservation system promises to push storage and transport window from hours to five days, without freezing or toxic additives.

As specialty drug spend tops 50% of pharmacy costs, health system specialty pharmacies are evolving from dispensers into longitudinal care management partners.

USP's Annual Drug Shortages Report reveals a sharp rise in product discontinuations, driven by unsustainable generic pricing, upstream geographic concentration, and manufacturing complexity.

Danny Williams breaks down direct-to-patient distribution and his outlook on where pharma 3PLs are headed over the next five years.

After adding 160 more drugs, TrumpRx tops 800 prescription offerings. Here's what the latest MFN-driven expansion means for pricing and access.

Danny Williams discusses how AI has moved from experimental pilots to full operational deployment across supply chain functions, and how cell and gene therapies are reshaping the logistics industry.

4flow's Natalia Andreyeva breaks down the persistent planning failures driving AI adoption in pharma supply chains.